Vaxart, Inc. (NASDAQ:VXRT) Short Interest Up 17.0% in February

Vaxart, Inc. (NASDAQ:VXRT) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 13,280,000 shares, a growth of 17.0% from the February 13th total of 11,350,000 shares. Currently, 6.0% of the shares of the stock are short sold. Based on an average daily volume of 1,960,000 shares, the short-interest ratio is presently 6.8 days.

Institutional Trading of Vaxart

Large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC grew its holdings in shares of Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 251,789 shares during the period. Graham Capital Management L.P. boosted its holdings in Vaxart by 155.8% in the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 32,482 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Vaxart by 10.8% in the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 17,942 shares during the period. Silverarc Capital Management LLC increased its holdings in shares of Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock worth $714,000 after buying an additional 77,782 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Vaxart during the 4th quarter valued at approximately $129,000. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

Vaxart Stock Performance

NASDAQ:VXRT opened at $0.58 on Thursday. Vaxart has a one year low of $0.45 and a one year high of $1.41. The stock has a market cap of $132.85 million, a PE ratio of -1.42 and a beta of 1.69. The stock has a 50 day moving average price of $0.66 and a 200 day moving average price of $0.71.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.